

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
7 October 2004 (07.10.2004)

PCT

(10) International Publication Number
WO 2004/085401 A1

(51) International Patent Classification⁷: **C07D 215/14**,
215/50, 215/12, 241/42, 401/04, 401/12, 409/12, 405/12,
413/12, 417/12, 403/06, 401/06, 413/06, 405/06, 417/06

(21) International Application Number:
PCT/IB2004/000836

(22) International Filing Date: 15 March 2004 (15.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/458,274 28 March 2003 (28.03.2003) US

(71) Applicant (for all designated States except US): **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHANG, George** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **DIDIUK, Mary, Theresa** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **FINNEMAN, Jari, Ilmari** [FI/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **GARIGIPATI, Ravi, Shanker** [US/US];

Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **KELLEY, Ryan, Michael** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **PERRY, David, Austen** [GB/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **RUGGERI, Roger, Benjamin** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **BECHLE, Bruce, Michael** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US).



(74) Agents: **LUMB, Trevor, J.** et al.; c/o LAWRENCE, Jackie, Pfizer Inc., Mailstop 8260-1615, Eastern Point Road, Groton, CT 06340 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: 1,2,4-SUBSTITUENTE 1,2,3,4-TETRAHYDRO-AND 1,2 DIHYDRO-QUINOLINE AND 1,2,3,4-TETRAHYDRO-QUINOXALINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND OBESITY



(57) Abstract: Quinoline and quinoxaline compounds of formula I and III wherein the substituent are as defined in claims 1 and 15, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.



Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *with international search report*